0.00Open1.45Pre Close0 Volume2 Open Interest9.00Strike Price0.00Turnover452.26%IV-7.60%PremiumJul 26, 2024Expiry Date2.31Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8212Delta0.0793Gamma4.27Leverage Ratio-0.2943Theta0.0003Rho3.50Eff Leverage0.0019Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet